AI-driven software for early detection of cardiovascular diseases using electrocardiography.

Tool: ECG-AI™ LEF
Description: AI-driven software for early detection of cardiovascular diseases using electrocardiography.
Summary: ECG-AI™ LEF by Anumana utilizes advanced AI algorithms to analyze electrocardiogram (ECG) data for the early detection of cardiovascular diseases, including low ejection fraction, which is indicative of heart failure. This tool is designed to aid physicians in identifying at-risk patients earlier, enabling timely intervention and potentially improving patient outcomes. Anumana's technology is built on a foundation of extensive electrophysiological data and validated through clinical research.
Category: Diagnostics
Tags: Diagnostics, Predictive Analytics
Use Cases: Physicians use ECG-AI™ LEF to detect early signs of heart failure in patients with no apparent symptoms.; Cardiologists incorporate ECG-AI™ LEF into routine screenings to improve the detection rates of cardiovascular diseases.
Platform: Web
Vendor: Anumana
Target Users: Clinician
Pricing: unclear
Regulatory: FDA 510(k) cleared
Meta: ECG-AI™ LEF by Anumana aids in the early detection of cardiovascular diseases using AI to analyze ECG data, improving early intervention.
Content: [![Anumana Logo](https://www.anumana.ai/anumana-logo.svg)](https://www.anumana.ai/) [ECG-AI™ LEF](https://www.anumana.ai/ecg-ai-lef) Resources Existing Customers [News](https://www.anumana.ai/newsroom) [Team](https://www.anumana.ai/about-us) Let's Connect Philips Launches ECG AI Marketplace to Enhance Early Cardiac Diagnosis [See Release](https://anumana.ai/newsroom/aHkLdxoAAEgATljJ) # Unlocking the language of the heart Harnessing the power of the electrical signal of the heart to transform cardiac care through cutting-edge AI solutions ![divider](https://www.anumana.ai/homepageImages/divider.svg) #### Anumana™ is an AI-driven health technology company from nference, building and commercializing AI solutions to improve patient care throughout the cardiac care continuum. # Our Impact #### The Impact of AI Algorithms in Cardiology Listen to Dr. Paul Friedman, a Professor of Medicine and Chair of the Department of Cardiovascular Medicine at Mayo Clinic and Anumana advisor, discuss the potential of AI algorithms in advancing early diagnosis and intervention in cardiology. ### Diagnostic Electrocardiography ![](https://images.prismic.io/anumana/c4000c30-82a4-4d0c-8697-c75e24839eb4_Untitled_Artwork+3+1.png?auto=compress,format) Serious cardiovascular diseases affect millions of people worldwide, often going undiagnosed until symptoms advance and patients deteriorate, at times resulting in life-threatening events and creating a multi-billion dollar healthcare burden. Anumana’s AI solutions enable earlier diagnosis of these otherwise hidden diseases, empowering clinicians to intervene with treatments earlier and improve outcomes. ### Electrophysiology ![](https://images.prismic.io/anumana/5cdc61cd-06c0-4004-bf17-89fa16ad8383_Untitled_Artwork+2+2.png?auto=compress,format) Today, the power of AI is just beginning to be leveraged in clinical decision support and has the potential to provide immense value during interventional procedures.​ Anumana is developing novel technologies that intend to enhance the precision and effectiveness of complex cardiac interventions and offer a new approach to intraoperative decision support. ![divider](https://www.anumana.ai/homepageImages/divider.svg) # Our Difference ![](data:image/svg+xml,%3csvg%20xmlns=%27http://www.w3.org/2000/svg%27%20version=%271.1%27%20width=%27603%27%20height=%27240%27/%3e)![](https://www.anumana.ai/_next/image?url=https%3A%2F%2Fimages.prismic.io%2Fanumana%2F4fcf95f3-cbb5-4c4e-9177-fad846852ac7_Structured%2BLabeled%2BData.png%3Fauto%3Dcompress%2Cformat&w=1920&q=75) ###### Rich, Proprietary Data Fueled R&D Anumana leverages the largest combined dataset of electrophysiological data, longitudinal patient history, and outcomes in the world. This dataset was developed from multi-year, exclusive data partnerships with leading academic medical centers from Anumana’s parent company, nference. This real-world evidence generation platform, nSights, is inclusive of 11M patients spanning 20+ years and transfo

ECG-AI™ LEF by Anumana aids in the early detection of cardiovascular diseases using AI to analyze ECG data, improving early intervention.

ECG-AI™ LEF

ECG-AI™ LEF by Anumana utilizes advanced AI algorithms to analyze electrocardiogram (ECG) data for the early detection of cardiovascular diseases, including low ejection fraction, which is indicative of heart failure. This tool is designed to aid physicians in identifying at-risk patients earlier, enabling timely intervention and potentially improving patient outcomes. Anumana's technology is built on a foundation of extensive electrophysiological data and validated through clinical research.

ECG-AI™ LEF

Categories

Description

Summary

Use Cases

Platforms

Regulatory Status

API Available

Added to Directory

Target Customer